For Episode 36 of the BioRevolution podcast, Andreas Horchler and Louise von Stechow are joined by Lia Carlucci, CEO of Food campus Berlin to discuss the future of food from alternative proteins and personalized nutrition and how the technologies of the BioRevolution, such as genomics and glucose sensing can aid those efforts.
For Episode 35 of the BioRevolution podcast, Andreas Horchler and Louise von Stechow are joined by idalab founder Paul von Bünau to discuss leadership in the age of AI, touching on the potential of AI for biotech and how leaders can adapt processes and help their staff adapt to the new challenges that AI will bring and dive into the question if AI has the potential to make us better leaders.
For Episode 33 of the BioRevolution podcast, Andreas Horchler and Louise von Stechow are joined by CTO and co-founder of Berlin-based biotech LUCID Genomics, Dr. Hossein Moeinzadeh, to discuss the exciting field of non-coding DNA and how LUCID’s AI algorithm can help make sense of non-coding DNA — and how this could improve diagnoses of rare diseases and beyond.
After a decades-long hiatus, research on psychedelics as a treatment for psychiatric diseases is experiencing a renaissance—and initial results look promising.
In the newest episode of the BioRevolution podcast, Andreas Horchler and Louise von Stechow discuss the history, the promise, and the risks of psychedelics as treatments for psychiatric diseases with neuroscientist, psychedelics expert, and executive coach Galyna Pidpruzhnykova
The value of facts and evidence-based science seems to be increasingly questioned by those in power and by those in control of assets. If those who make laws and regulate science don’t see evidence and consensus as reliable resources anymore, what will become of progress in biomedicine, which feeds innovation in biotech, pharma, and medicine?
For Episode 36 of the BioRevolution podcast, Andreas Horchler and Louise von Stechow are joined by Lia Carlucci, CEO of Food campus Berlin to discuss the future of food from alternative proteins and personalized nutrition and how the technologies of the BioRevolution, such as genomics and glucose sensing can aid those efforts.
